Petros pharmaceuticals provides letter to shareholders

New york, ny / accesswire / september 11, 2023 / petros pharmaceuticals, inc. (nasdaq:ptpi), a company focused on expanding consumer access to medication through over the counter (otc) pathway provides the below letter to shareholders: to our valued shareholders, as we approach the fourth quarter of 2023, petros has been quietly undergoing a change in approach to our business. as we have previously announced, our evolving focus has shifted from prioritizing the commercialization of prescription stendra, which continues to be a source of revenue for us, to developing and executing on a new pathway toward non-prescription or potentially over-the-counter access for our current lead product.
PTPI Ratings Summary
PTPI Quant Ranking